NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses

SYFPEITHI: database for MHC ligands and peptide motifs

1999 • 2,307 citations

A PROSPECTIVE, RANDOMIZED TRIAL OF AUTOLOGOUS BONE MARROW TRANSPLANTATION AND CHEMOTHERAPY IN MULTIPLE MYELOMA

2013 • 2,176 citations

High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma

2003 • 1,759 citations

Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains.

1994 • 1,400 citations

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

1997 • 1,235 citations

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

1993 • 986 citations

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.

1994 • 850 citations

Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma

2004 • 807 citations

Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes

1998 • 728 citations

A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens

1998 • 712 citations

Genetics and Cytogenetics of Multiple Myeloma

2004 • 698 citations

The role of CD4+ T cell responses in antitumor immunity

1998 • 678 citations

The cancer/testis genes: review, standardization, and commentary.

2004 • 670 citations

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

2002 • 655 citations

Superiority of Tandem Autologous Transplantation Over Standard Therapy for Previously Untreated Multiple Myeloma

1997 • 576 citations

Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.

1995 • 552 citations

Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma

1999 • 499 citations

Treatment of multiple myeloma

2003 • 474 citations

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

2004 • 446 citations

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers

2000 • 435 citations

Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities

1995 • 418 citations

Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses

2000 • 407 citations

In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression

2003 • 388 citations

CD4⁺T cells eliminate MHC class II-negative cancer cellsin vivoby indirect effects of IFN-γ

1999 • 378 citations

Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues

2001 • 351 citations

Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities

2000 • 333 citations

Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy

2002 • 324 citations

Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study

2000 • 317 citations

Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library

1998 • 307 citations

Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+ T Lymphocytes

1999 • 242 citations

Humoral immune responses of cancer patients against “Cancer-Testis” antigen NY-ESO-1: Correlation with clinical events

1999 • 230 citations

Genes encoding tumor-specific antigens are expressed in human myeloma cells

1999 • 201 citations

Survey of naturally occurring CD4 ⁺ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses

2003 • 201 citations

CD4⁺T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody production

2001 • 199 citations

Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.

2000 • 192 citations

Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants.

1997 • 187 citations

Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL

2000 • 172 citations

Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays

2002 • 172 citations

Antigens recognized by autologous antibody in patients with renal-cell carcinoma

1999 • 170 citations

Dose-Intensive Melphalan With Stem Cell Support (MEL100) Is Superior to Standard Treatment in Elderly Myeloma Patients

1999 • 163 citations

Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization‐defined chromosome 13 deletion in multiple myeloma: early results of total therapy II

2002 • 159 citations

Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts

2002 • 156 citations

Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes.

1995 • 145 citations

Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers

2001 • 141 citations

Identification of New Epitopes from Four Different Tumor-Associated Antigens: Recognition of Naturally Processed Epitopes Correlates with HLA-A∗0201-Binding Affinity

2001 • 136 citations

Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression

2003 • 134 citations

Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease.

2003 • 133 citations

NY-ESO-1 Expression and Immunogenicity in Malignant and Benign Breast Tumors

2004 • 99 citations

Predicting long‐term (≥ 5 years) event‐free survival in multiple myeloma patients following planned tandem autotransplants

2002 • 93 citations

Immunodominant CD4 ⁺ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant

2004 • 92 citations

Identification of immunodominant regions among promiscuous HLA-DR–restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3

2003 • 90 citations

NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens

2000 • 77 citations

Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer.

2003 • 75 citations

Identification of NY‐ESO‐1, MAGE‐1, and MAGE‐3 in head and neck squamous cell carcinoma

2003 • 73 citations

Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment

1997 • 72 citations

Analysis of Cancer/Testis Antigens in Sporadic Medullary Thyroid Carcinoma: Expression and Humoral Response to NY-ESO-1

2003 • 69 citations

Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.

2003 • 67 citations

NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer.

2003 • 64 citations

The PTEN pathway in Tregs functions as a critical driver of the immunosuppressive tumor microenvironment and tolerance to apoptotic cells

2015 • 56 citations

Induction of Tumor-Reactive Cytotoxic T-Lymphocytes Using a Peptide from NY-ESO-1 Modified at the Carboxy-terminus to Enhance HLA-A2.1 Binding Affinity and Stability in Solution

2001 • 40 citations

Expression of Cancer/Testis Tumor Associated Antigens in Cervical Squamous Cell Carcinoma

2003 • 34 citations

Tumour‐associated antigens in multiple myeloma

2002 • 32 citations

SEREX analysis of gastric cancer antigens

2000 • 27 citations

Early results of total therapy II in multiple myeloma: Implications of cytogenetics and FISH

2002 • 19 citations